T. Brannan et al., EFFECT OF REPEATED ELECTROCONVULSIVE SHOCK ON STRIATAL L-DOPA AND DOPAMINE METABOLISM - AN IN-VIVO STUDY, Journal of neural transmission. Parkinson's disease and dementia section, 6(1), 1993, pp. 35-44
A course of treatments with electroconvulsive shock (ECS) has been rep
orted to reestablish L-dopa efficacy in patients with advanced Parkins
on's disease. We wished to determine if ECS could modify L-dopa and do
pamine metabolism in an animal model of Parkinson's disease. Therefore
, we administered repeated ECS (8 ECS at 48 hr intervals) to rats with
partial destruction of the nigrostriatal dopamine pathway and used th
e cerebral microdialysis technique to monitor extracellular concentrat
ions of dopamine and dopamine metabolites (DOPAC and HVA) in the corpu
s striatum. The control group of animals received sham-ECS treatments.
Basal dopamine levels were decreased by 20% in animals receiving repe
ated-ECS versus sham-ECS. DOPAC levels, on the other hand, were increa
sed by 84% in animals receiving repeated-ECS. HVA levels were equal in
the two groups. Following L-dopa administration, dopamine and HVA lev
els increased equally in control animals and animals which had previou
sly received repeated-ECS. DOPAC concentrations were uniformly greater
in rats receiving repeated-ECS. When ECS was administered acutely, do
pamine levels increased 390% and returned to baseline values in 75 min
utes, DOPAC and HVA were unchanged, and 5HIAA levels decreased 30%. We
conclude that 1) acute ECS administration produces a transient, marke
d release of striatal dopamine and 2) repeated ECS can reset the level
of basal dopamine release, a finding compatible with ECS-induced dopa
mine receptor supersensitivity, and 3) neither single nor repeated adm
inistration of ECS has a major effect on the formation of dopamine or
HVA from exogenously administered L-dopa although there was a strong t
endency for increased DOPAC formation. ECS may exert its putative anti
parkinsonian effect by enhancing - dopamine receptor sensitivity.